Literature DB >> 18432410

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Hans Helmut Niller1, Hans Wolf, Janos Minarovits.   

Abstract

Epstein-Barr virus (EBV) is a human herpesvirus hiding in a latent form in memory B cells in the majority of the world population. Although, primary EBV infection is asymptomatic or causes a self-limiting disease, infectious mononucleosis, the virus is associated with a wide variety of neoplasms developing in immunosuppressed or immunodeficient individuals, but also in patients with an apparently intact immune system. In memory B cells, tumor cells, and lymphoblastoid cell lines (LCLs, transformed by EBV in vitro) the expression of the viral genes is highly restricted. There is no virus production (lytic viral replication associated with the expression of all viral genes) in tight latency. The expression of latent viral oncogenes and RNAs is under a strict epigenetic control via DNA methylation and histone modifications that results either in a complete silencing of the EBV genome in memory B cells, or in a cell-type dependent usage of latent promoters in tumor cells, germinal center B cells, and LCLs. Both the latent and lytic EBV proteins are potent immunogens and elicit vigorous B- and T-cell responses. In immunosuppressed and immunodeficient patients, or in individuals with a functional defect of EBV-specific T cells, lytic EBV replication is regularly activated and an increased viral load can be detected in the blood. Enhanced lytic replication results in new infection events and EBV-associated transformation events, and seems to be a risk factor both for malignant transformation and the development of autoimmune diseases. One may speculate that an increased load or altered presentation of a limited set of lytic or latent EBV proteins that cross-react with cellular antigens triggers and perpetuates the pathogenic processes that result in multiple sclerosis, systemic lupus erythematosus (SLE), and rheumatoid arthritis. In addition, in SLE patients EBV may cause defects of B-cell tolerance checkpoints because latent membrane protein 1, an EBV-encoded viral oncoprotein can induce BAFF, a B-cell activating factor that rescues self-reactive B cells and induces a lupus-like autoimmune disease in transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18432410     DOI: 10.1080/08916930802024772

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  63 in total

Review 1.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

2.  Assessment of Epstein-Barr virus in blood from patients with multiple sclerosis.

Authors:  Gloudina M Hon; Mogamat S Hassan; Susan J van Rensburg; Rajiv T Erasmus; Tandi E Matsha
Journal:  Metab Brain Dis       Date:  2012-03-10       Impact factor: 3.584

3.  Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis.

Authors:  Paula S Ramos; Elisabeth E Brown; Robert P Kimberly; Carl D Langefeld
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

4.  Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis.

Authors:  Costanza Casiraghi; Ana Citlali Márquez; Iryna Shanina; Marc Steven Horwitz
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

Review 5.  Heterogeneous pathways of maternal-fetal transmission of human viruses (review).

Authors:  A Saleh Younes; Márta Csire; Beatrix Kapusinszky; Katalin Szomor; Mária Takács; György Berencsi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

6.  Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism.

Authors:  Xiaoping Sun; Elizabeth A Barlow; Shidong Ma; Stacy R Hagemeier; Sarah J Duellman; Richard R Burgess; Judy Tellam; Rajiv Khanna; Shannon C Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

7.  Alpha beta-crystallin expression and presentation following infection with murine gammaherpesvirus 68.

Authors:  Vinita S Chauhan; Daniel A Nelson; Ian Marriott; Kenneth L Bost
Journal:  Autoimmunity       Date:  2013-04-16       Impact factor: 2.815

8.  Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice.

Authors:  Michael L Freeman; Claire E Burkum; Kathleen G Lanzer; Alan D Roberts; Mykola Pinkevych; Asako Itakura; Lawrence W Kummer; Frank M Szaba; Miles P Davenport; Owen J T McCarty; David L Woodland; Stephen T Smiley; Marcia A Blackman
Journal:  J Autoimmun       Date:  2012-12-14       Impact factor: 7.094

9.  Concept and application of a computational vaccinology workflow.

Authors:  Johannes Söllner; Andreas Heinzel; Georg Summer; Raul Fechete; Laszlo Stipkovits; Susan Szathmary; Bernd Mayer
Journal:  Immunome Res       Date:  2010-11-03

10.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.